Beck, M. http://orcid.org/0000-0003-2523-6266
Hartwich, J.
Eckstein, M.
Schmidt, D.
Gostian, A. O.
Müller, S.
Rutzner, S.
Gaipl, U. S.
von der Grün, J.
Illmer, T.
Hautmann, M. G.
Klautke, G.
Döscher, J.
Brunner, T.
Tamaskovics, B.
Hartmann, A.
Iro, H.
Kuwert, T.
Fietkau, R.
Hecht, M.
Semrau, S.
Clinical trials referenced in this document:
Documents that mention this clinical trial
F18-FDG PET/CT imaging early predicts pathologic complete response to induction chemoimmunotherapy of locally advanced head and neck cancer: preliminary single-center analysis of the checkrad-cd8 trial
https://doi.org/10.1007/s12149-022-01744-6
Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8
https://doi.org/10.1136/jitc-2020-001378
Induction chemoimmunotherapy followed by CD8+ immune cell-based patient selection for chemotherapy-free radioimmunotherapy in locally advanced head and neck cancer
https://doi.org/10.1136/jitc-2021-003747
Funding for this research was provided by:
AstraZeneca (ESR-16-12356)
Friedrich-Alexander-Universität Erlangen-Nürnberg
Article History
Received: 1 February 2022
Accepted: 12 April 2022
First Online: 10 May 2022
Declarations
:
: M.B. conflict of interest with Novartis (travel expenses); Bayer (advisory role, honoraria); SIRTEX (travel expenses). J.H. has no conflict of interest. M.E. conflict of interest with Diaceutics (employment, honoraria, advisory role, speakers’ bureau, travel expenses); AstraZeneca (honoraria, advisory role, speakers’ bureau, travel expenses); Roche (honoraria, travel expenses); MSD (honoraria, speakers’ bureau); GenomicHealth (honoraria, advisory role, speakers bureau, travel expenses); Astellas (honoraria, speakers’ bureau); Janssen-Cilag (honoraria, advisory role, research funding, travel expenses); Stratifyer (research funding, patents). D.S. has no conflict of interest. A.O.G. has no conflict of interest. S.M. has no conflict of interest. S.R. conflict of interest with AstraZeneca (research funding); MSD (research funding). U.S.G. conflict of interest with AstraZeneca (advisory role, research funding); BMS (advisory role); MSD (research funding); Sennewald Medizintechnik (travel expenses). J.G. has no conflict of interest. I.T. has no conflict of interest. M.G.H. conflict of interest with Roche (stock, honoraria); Varian (stock); Sanofi (honoraria); AstraZeneca (honoraria, travel expenses); BMS (honoraria, advisory role); MSD (honoraria, advisory role); Merck Serono (honoraria); Celgene (honoraria). G.K. conflict of interest with BMS (advisory role); Lilly (advisory role); Roche (advisory role). J.D. has no conflict of interest. B.T. conflict of interest with BMS (honoraria, advisory role, travel expenses); Merck Serono (honoraria, advisory role); MSD (travel expenses). A.H. conflict of interest with BMS (honoraria, advisory role); MSD (honoraria, advisory role); Roche (honoraria, advisory role, research funding); AstraZeneca (honoraria, advisory role, research funding); Boehringer Ingelheim (honoraria); Abbvie (honoraria); Cepheid (advisory role, research funding); Quiagen (advisory role); Janssen-Cilag (honoraria, advisory role, research funding); Ipsen (honoraria, advisory role); NanoString Technologies (advisory role, research funding, expert testimony); Illumina (advisory role); 3DHistech (advisory role); Diaceutics (advisory role); BioNTech (research funding). H.I. has no conflict of interest. T.K. conflict of interest with Siemens Healthineers (advisory role, honoraria, speakers’ bureau, travel expenses, research funding). R.F. conflict of interest with MSD (honoraria, advisory role, research funding, travel expenses); Fresenius (honoraria); BrainLab (honoraria); AstraZeneca (honoraria, advisory role, research funding, travel expenses); Merck Serono (advisory role, research funding, travel expenses); Novocure (advisory role, speakers’ bureau, research funding); Sennewald (speakers’ bureau, travel expenses). The other authors declare no conflicts of interest. M.H. conflict of interest with Merck Serono (advisory role, speakers’ bureau, honoraria, travel expenses, research funding); MSD (advisory role, speakers’ bureau, travel expenses, research funding); AstraZeneca (research funding); Novartis (research funding); BMS (advisory role, honoraria, speakers’ bureau); Teva (travel expenses). S.S. conflict of interest with Strycker (stock); Varian (stock); Abbot (stock); Crispr Techn. (stock); Pfitzer (stock); Merck Serono (stock); Symrise (stock); Ortho (honoraria, advisory role, speakers’ bureau, research funding, travel expenses); PharmaMar (speakers’ bureau, travel expenses); Haema (speakers’ bureau).
: The trial was registered with ClinicalTrials.gov (identifier: NCT03426657). The institutional review board at the Friedrich-Alexander-Universität Erlangen-Nürnberg (number: 131_18 Az) approved the trial. All patients gave written informed consent to the study and to publication. The trial was funded by AstraZeneca (ESR-16-12356) and was conducted as investigator sponsored trial. The study was carried out in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments.